Treatment of MIS-C Survey

Survey Date (auto-populates; not seen by user)
Thank you for agreeing to participate in this multi-center survey aimed at capturing the protocolized evaluation and management of Multisystem Inflammatory Syndrome in Children (MIS-C). In the absence of published guidelines, many centers have created individual protocols to direct treatment of this condition. The goal of this survey is to better understand how centers are constructing their protocol. Our hope is to improve the care of MIS-C by sharing pediatric hospitals' information regarding the evaluation, management, and follow-up of these patients. For any questions or concerns related to this survey, please contact Dr. Matt Oster at osterm@kidsheart.com
First Name
Last Name
Role of person completing this form. Check all that apply. Cardiologist Intensive Care physician Infectious Disease physician Rheumatologist Hematologist General Pediatrician Administrator Fellow Resident Other (please specify)
Please specify your role.
Email
Direct Phone Number
May we contact you if we have questions about your responses? O Yes O No
What is the name of your center?

₹EDCap°

07-18-2020 8:12pm

What is your best estimate of the total MIS-C patients that your center has managed?
 ○ 0 ○ 1-5 patients ○ 6-10 patients ○ 11 -25 patients ○ >25 patients ○ Not sure
How many pediatric beds does your hospital have?
Where is your center located?
Has your center developed an MIS-C protocol to guide evaluation and treatment?
Date of initial protocol
Has the protocol changed since it was initially created?
○ Yes ○ No ○ Not sure
What changes were made to the protocol and why?
Date of most recent protocol
Is it possible to receive a copy of your current protocol?
Please attach a copy of your current protocol.
Can we publish this protocol as part of a supplement to a manuscript?
○ Yes○ No○ Not sure



We plan to invite one person from each center that provides a copy of their protocol to be published to be included as a co-author in any manuscript that arises from this survey. Would you be interested in being considered?
○ Yes ○ No
Please answer the remainder of the survey according to your center's protocol.
Please answer the remainder of the survey based on what your center typically does for patients suspected of having MIS-C.
Definition of MIS-C and Inclusions Criteria for diagnosis of MIS-C
Does the definition or inclusion criteria for MIS-C at your center specify the presence of fever?
○ Yes ○ No
What are minimum days of fever required?
○ 1 ○ 2 ○ 3 ○ 4 ○ 5
Is there a minimum temperature specified for fever?
○ Yes ○ No
What is the minimum temperature?
Is this minimum temperature Celsius or Fahrenheit?
○ Celsius ○ Fahrenheit
Does the inclusion criteria specify the presence of symptoms of certain organ systems or clinical features?
○ Yes ○ No
How many organ systems/clinical features must be involved?



Which organ systems/clinical features are included as potentially meeting criteria for MIS-C at your center? Check all that apply.
 □ Cardiac (e.g. tachycardia, shock, chest pain) □ Dermatologic (e.g. rash) immune (e.g. lymphadenopathy) □ Extremity changes (e.g. swelling or edema of hands and feet) □ Gastrointestinal (e.g. abdominal pain, nausea, vomiting) □ Neurological (e.g. headache, altered mental status, seizure) □ Ocular (e.g. conjunctivitis) □ Oral Mucosa (e.g. dry or cracked lips, strawberry tongue) □ Respiratory (e.g. cough, shortness of breath) □ Other
Please specify other organ systems/clinical features.
Does the inclusion criteria specify age?
○ Yes ○ No
Please specify the upper age range (in years).
Please specify the lower age range (in years).
Is the lower age in months or years?
Does the inclusion criteria specify the presence of abnormal labs?
○ Yes ○ No
How many lab findings must be abnormal?
○ 1 ○ 2 ○ 3 ○ 4 ○ >4



Which abnormal labs are included as potentially meeting criteria for MIS-C at your center? Check all that apply.
□ Elevated CRP □ Elevated white blood cell count □ Neutrophilia □ Lymphopenia □ Thrombocytopenia □ Anemia □ Hyponatremia □ Elevated Creatinine □ Elevated BNP or proBNP □ Elevated Troponin □ Hypoalbuminemia □ Elevated AST or ALT □ Elevated ferritin □ Elevated D-Dimer □ Pyuria □ Other
Please specify other lab criteria included.
Is positive SARS-CoV-2 testing required for inclusion?
○ Yes ○ No
Is prior exposure to someone with COVID required?
○ Yes ○ No
What positive SARS-CoV-2 testing meets inclusion criteria? Check all that apply.
 Nasopharyngeal/Oropharyngeal PCR Stool PCR IgA Antibody IgG Antibody IgM Antibody Antigen Testing Other
Please specify other positive SARS-CoV-2 testing that meets inclusion criteria.
Do you know the specific Antibody test (company and any other information) that your hospital uses?
○ Yes ○ No
Please specify the Antibody test that your hospital uses.
Comments regarding inclusion criteria for diagnosis of MIS-C

₹EDCap°

Evaluation of Patients with Suspected or Confirmed MIS-C Option to select for ALL patients or Only Selected Patients

Including initial labs	s, what labs are	ordered for	patients wit	h concern	for MIS-C?
------------------------	------------------	-------------	--------------	-----------	------------

	Some Patients	All Patients
CBC w/ diff	\circ	\circ
Chem panel	\circ	\circ
LFTs	\bigcirc	\circ
CRP	\bigcirc	\circ
ESR	\bigcirc	\circ
Urinalysis (with reflex culture)	\bigcirc	\circ
Urine creatinine and protein	\bigcirc	\circ
BNP or proBNP	\bigcirc	\circ
Troponin	\bigcirc	\circ
CK-MB	\bigcirc	\circ
Ferritin	\bigcirc	\circ
D-dimer	\circ	\circ
Protime and INR	\circ	\circ
aPTT	\circ	\circ
Von Willebrand antigen	\bigcirc	\circ
Blood culture	\circ	\circ
Procalcitonin	\bigcirc	\circ
LDH	\bigcirc	\circ
Triglycerides	\bigcirc	\circ
Amylase	\bigcirc	\circ
Lipase	\bigcirc	\circ
Vitamin D level	\bigcirc	0
Cytokine panel	\bigcirc	0
IL-6	\bigcirc	0
ANA	\circ	0
C3	\bigcirc	\circ
C4	0	0
CXCL9	0	0
Respiratory viral panel		0
CMV PCR	0	0
EBV PCR	0	
Parvovirus PCR	0	O O
Adenovirus PCR	0	0
SARS-CoV-2:	0	\bigcirc
Nasopharyngeal/Oropharyngeal	\mathcal{O}	\bigcirc
PCR		



SARS-CoV-2: Stool PCR	\bigcirc	\bigcirc
SARS-CoV-2: IgA Antibody	\bigcirc	\circ
SARS-CoV-2: IgG Antibody	\bigcirc	\circ
SARS-CoV-2: IgM Antibody	\circ	\circ
SARS-CoV-2: Antigen Testing	\circ	\circ
Other	\circ	\circ
Please specify what other labs are order	ered for patients with concern for MIS-0	2.
What imaging studies are typically orde	ered for patients with concern for MIS-	C?
	Some Patients	All Patients
CXR	\bigcirc	\circ
EKG	\bigcirc	\circ
Echocardiogram	\circ	\circ
Abdominal Ultrasound	\circ	\circ
Chest CT	\circ	\circ
Abdominal CT	\circ	\circ
Other	0	\circ
Please specify what other supplementa	il imaging/procedures are obtained.	
What consulting services are typically of	ordered for patients with concern for M	IIS-C?
	Some of the Patients	All of the Patients
Cardiology	\bigcirc	\circ
Infectious Disease	\bigcirc	\circ
Rheumatology	\bigcirc	\circ
Hematology	\bigcirc	\circ
Nephrology	\circ	\circ
Other	0	0
Please specify what other consults are	ordered.	
Comments regarding evaluation of pat	ients with suspected or confirmed MIS-	-C
Management		



Which of the following treatments are routinely given?				
	Mild cases	Moderate cases	Severe cases	Use Regardless of Severity
IVIG				
Corticosteroids				
Aspirin				
Heparin/LMWH				
Clopidogrel (Plavix)				
Warfarin (Coumadin)				
Anakinra (IL-1 inhibitor)				
Tocilizumab (IL-6 inhibitor)				
Antibiotics				
Remdesivir				
Hydroxychloroquine				
Vasopressors				
Other				
Other Treatment Name				_
Medication Dosage Per Severity				
IVIG: Mild Dosage Amount:				
IVIG: Moderate Dosage Amount:				
IVIG: Severe Dosage Amount:				
IVIG Dosage Amount:				
Corticosteroids: Mild Dosage Amou	nt & Agent:			
Corticosteroids: Moderate Dosage A	Amount & Agent:			
Corticosteroids: Severe Dosage Am	ount & Agent: :			_
Corticosteroids Dosage Amount & A	Agent: :			_
Aspirin: Mild Dosage Amount:				



Aspirin: Moderate Dosage Amount:	
Aspirin: Severe Dosage Amount:	
Aspirin Dosage Amount:	
Heparin/LMWH: Mild Prophylactic Dose or Targeted Therapeutic Level :	
Heparin/LMWH: Moderate Prophylactic Dose or Targeted Therapeutic Level :	
Heparin/LMWH: Severe Prophylactic Dose or Targeted Therapeutic Level :	
Heparin/LMWH Prophylactic Dose or Targeted Therapeutic Level :	
Plavix: Mild Dosage Amount:	
Plavix: Moderate Dosage Amount:	
Plavix: Severe Dosage Amount:	
Plavix Dosage Amount:	
Warfarin: Mild Dosage Amount:	
Warfarin: Moderate Dosage Amount:	
Warfarin: Severe Dosage Amount:	
Warfarin: Severe Dosage Amount:	
Warfarin: Severe Dosage Amount: Anakinra: Mild Dosage Amount:	



Anakinra Dosage Amount:	
Tocilizumab: Mild Dosage Amount:	
Tocilizumab: Moderate Dosage Amount:	
Tocilizumab: Severe Dosage Amount:	
Tocilizumab Dosage Amount:	
Antibiotics: Mild Dosage Amount and Name of Drug:	
Antibiotics: Moderate Dosage Amount and Name of Drug:	
Antibiotics: Severe Dosage Amount and Name of Drug:	
Antibiotics Dosage Amount and Name of Drug:	
Remdesivir: Mild Dosage Amount:	
Remdesivir: Moderate Dosage Amount:	
Remdesivir: Severe Dosage Amount:	
Remdesivir Dosage Amount:	
Hydroxychloroquine: Mild Dosage Amount:	
Hydroxychloroquine: Moderate Dosage Amount:	
Hydroxychloroquine: Severe Dosage Amount:	
Hydroxychloroquine Dosage Amount:	
Vasopressors: Mild Dosage Amount and Name of Drug:	



Vasopressors: Moderate Dosage Amount and Name of Drug:		
Vasopressors: Severe Dosage Amount and Name of Drug:		
Vasopressors Dosage Amount and Name of Drug:		
[tx_other_name]: Mild Dosage Amount:		
[tx_other_name]: Moderate Dosage Amount:		
[tx_other_name]: Severe Dosage Amount:		
[tx_other_name] Dosage Amount:		
How is severity defined at your center?		
If patient does not improve with first dose of IVIG, is a 2nd dose re	ecommended?	
○ Yes ○ No		
Does your center use a maximum dose for IVIG?		
○ Yes ○ No		
What is the maximum dose?		
Comments regarding management of patients with suspected or o	confirmed MIS-C:	
Follow-Up		
Are your MIS-C follow-up guidelines the same as the published AH	A Kawasaki Disease guidelines?	
○ No○ Yes○ I don't know		



Do your follow-up guidelines va	ry by presence of corona	ary involvement?		
○ Yes ○ No				
What medications are patients	routinely discharged hor	me on?		
	Mild/Small Coronary Dilation	Moderate/Medium Coronary Dilation	Severe/Large Coronary Dilation	Use Regardless of Severity
Aspirin				
LMWH				
Plavix				
Warfarin				
Other				
Other Treatment Name				_
Discharge Medication Dosage P	er Severity			
Aspirin: Mild Dosage Amount:				_
Aspirin: Moderate Dosage Amou	unt:			_
Aspirin: Severe Dosage Amount	:			_
Aspirin Dosage Amount:				_
LMWH: Mild Prophylactic Dose of Level:	or Targeted Therapeutic			_
LMWH: Moderate Prophylactic D Therapeutic Level:	Pose or Targeted			_
LMWH: Severe Prophylactic Dos Therapeutic Level:	e or Targeted			_
LMWH Prophylactic Dose or Tare	geted Therapeutic Level	:		_
Plavix: Mild Dosage Amount:				_
Plavix: Moderate Dosage Amou	nt:			_
Plavix: Severe Dosage Amount:				_
Plavix Dosage Amount:				



Warfarin: Mild Dosage Amount:		
Warfarin: Moderate Dosage Amount:		
Warfarin: Severe Dosage Amount:		
Warfarin Dosage Amount:		
[tx_other_coronary_name]: Mild Dosage Amount:		
[tx_other_coronary_name]: Moderate Dosage Amount:		
[tx_other_coronary_name]: Severe Dosage Amount:		
[tx_other_coronary_name] Dosage Amount:		
What specialty clinic visits are recommended? Check all that app	ly.	
☐ Cardiology ☐ Infectious Disease ☐ Rheumatology ☐ Hematology ☐ Nephrology ☐ Other		
What other service is recommended for patient follow up?		
For patients with cardiac involvement, when is outpatient echoca	rdiogram recommended?	
○ Within 1 week○ Within 2 weeks○ Within 1 month○ Within 3 months○ None		
For patients with LV dysfunction, does the protocol recommend c	ardiac MRI?	
○ No○ Yes, during hospitalization○ Yes, in 1-3 months○ Yes, in 3-6 months○ Other		
What other time period does the protocol recommend cardiac MF	kl?	



Is follow up cardiac MRI obtained for patients without LV dysfunction?
○ Yes ○ No
Comments regarding follow-up of patients with suspected or confirmed MIS-C
Any other comments regarding this survey?

